| Sector |
Healthcare
|
Compare with Sector peers |
| Industry |
Pharmaceuticals & Drugs
|
Compare with Industry peers |
| Website | http://www.sunpharma.com | |
| Market Cap | 355,317.52 Cr. | |
| Enterprise Value(EV) | 363,667.50 Cr. | 2023-09 |
| Financial Indicators | ||
|---|---|---|
| Earnings per share (EPS) | 37.12 | Trailing Twelve Months Ending 2023-12 |
| Price-Earning Ratio (PE) | 39.90 | Trailing Twelve Months Ending 2023-12 |
| Industry PE | 41.25 | Trailing Twelve Months Ending 2023-12 |
| Book Value / Share | 260.05 | Trailing Twelve Months Ending 2023-12 |
| Price to Book Value | 5.69 | Calculated using Price: 1,480.90 |
| Dividend Yield | 0.78 | Period Ending 2023-03 |
| No. of Shares Subscribed | 239.93 Cr. | 2,399,334,970 Shares |
| FaceValue | 1 | |
| About Sun Pharmaceutical Industries Ltd. | ||
| The company is among the largest specialty generic pharmaceutical company and India's top pharmaceutical company. A vertically integrated business and a skilled team enables it to deliver high-quality products, trusted by customers and patients in many countries across the world, at affordable prices. | ||
| 1 Day |
|
-3.60% |
| 1 Week |
|
-3.60% |
| 1 Month |
|
-7.72% |
| 3 Month |
|
+11.95% |
| 6 Month |
|
+29.98% |
| 1 Year |
|
+50.05% |
| 2 Year |
|
+60.54% |
| 5 Year |
|
+226.66% |
| 10 Year |
|
+139.48% |
| 9 years | 2015-03 | 2016-03 | 2017-03 | 2018-03 | 2019-03 | 2020-03 | 2021-03 | 2022-03 | 2023-03 | |
| Return on Equity (%) | 24.89 | 19.32 | 22.51 | 6.85 | 8.05 | 9.66 | 4.98 | 7.21 | 16.46 | |
| Return on Capital Employed (%) | 25.06 | 18.64 | 21.48 | 8.4 | 8.68 | 10.07 | 5.66 | 9.28 | 17.24 | |
| Return on Assets (%) | 14.6 | 11.39 | 14.08 | 4.24 | 5.17 | 6.58 | 3.54 | 5.2 | 11.85 |
| Particulars | 10 years | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. | 2023-09* Rs. Cr. |
| Shh. Funds | 25,638 | 32,982 | 36,640 | 38,314 | 41,409 | 45,264 | 46,463 | 48,011 | 55,995 | 59,826 | |
| Non Curr. Liab. | 2,335 | 2,170 | 600 | 46 | 77 | 246 | -1,515 | -1,316 | -1,643 | -1,971 | |
| Curr. Liab. | 16,147 | 13,144 | 17,887 | 19,864 | 17,340 | 15,706 | 16,146 | 17,208 | 19,906 | 15,023 | |
| Minority Int. | 2,851 | 4,085 | 3,791 | 3,884 | 3,314 | 3,860 | 3,017 | 3,055 | 3,320 | 3,371 | |
| Equity & Liab. | 46,972 | 52,381 | 58,917 | 62,109 | 62,139 | 65,077 | 64,110 | 66,958 | 77,579 | 76,249 | |
| Non Curr. Assets | 18,056 | 22,440 | 25,964 | 30,473 | 31,070 | 33,423 | 33,668 | 32,094 | 37,696 | 36,896 | |
| Curr. Assets | 28,916 | 29,934 | 32,947 | 31,636 | 31,069 | 31,654 | 30,442 | 34,865 | 39,862 | 39,354 | |
| Misc. Exp. not W/O | |||||||||||
| Total Assets | 46,972 | 52,381 | 58,917 | 62,109 | 62,139 | 65,077 | 64,110 | 66,958 | 77,579 | 76,249 |
| Particulars | 10 years | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. | 2023-12 Rs. Cr. TTM |
| Net Sales | 27,392 | 28,109 | 31,308 | 26,416 | 29,066 | 32,838 | 33,498 | 38,654 | 43,886 | 47,445 | |
| Other Income | 566 | 658 | 1,030 | 912 | 1,059 | 652 | 859 | 1,437 | 820 | 1,248 | |
| Total Income | 27,958 | 28,767 | 32,338 | 27,328 | 30,125 | 33,489 | 34,357 | 40,092 | 44,706 | 48,693 | |
| Total Expenditure | -19,543 | -19,950 | -21,626 | -20,881 | -22,792 | -25,863 | -25,030 | -28,773 | -32,424 | -34,781 | |
| PBIDT | 8,414 | 8,817 | 10,712 | 6,447 | 7,333 | 7,626 | 9,327 | 11,319 | 12,281 | 13,912 | |
| Interest | -579 | -523 | -400 | -518 | -555 | -303 | -141 | -127 | -172 | -258 | |
| Depreciation | -1,195 | -1,038 | -1,265 | -1,500 | -1,753 | -2,053 | -2,080 | -2,144 | -2,529 | -2,578 | |
| Taxation | -915 | -914 | -1,212 | -911 | -601 | -823 | -515 | -1,076 | -848 | -1,513 | |
| Exceptional Items | -238 | -685 | -951 | -1,214 | -261 | -4,306 | -4,567 | -171 | -564 | ||
| PAT | 5,488 | 5,657 | 7,836 | 2,568 | 3,209 | 4,187 | 2,285 | 3,406 | 8,561 | 8,999 | |
| Minority Interest | -936 | -1,113 | -882 | -447 | -542 | -407 | 631 | -117 | -39 | -28 | |
| Share Associate | -13 | 1 | 10 | -25 | -1 | -15 | -12 | -17 | -48 | -64 | |
| Other Related Items | |||||||||||
| Consolidated Net Profit | 4,539 | 4,546 | 6,964 | 2,096 | 2,665 | 3,765 | 2,904 | 3,273 | 8,474 | 8,906 | |
| Adjusted EPS | 22 | 19 | 29 | 9 | 11 | 16 | 12 | 14 | 35 | 37 |
| Particulars | 10 years | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. |
| Cash Fr. Operatn. | 3,959 | 5,616 | 6,686 | 7,082 | 3,907 | 2,196 | 6,555 | 6,170 | 8,985 | 4,959 | |
| Cash Fr. Inv. | -2,367 | -2,866 | -4,372 | -4,222 | -3,371 | -681 | -2,589 | 536 | -5,725 | -7,944 | |
| Cash Fr. Finan. | 507 | -1,187 | -1,889 | -2,285 | -1,539 | -2,731 | -5,715 | -5,980 | -5,193 | 2,376 | |
| Net Change | 2,099 | 1,563 | 426 | 575 | -1,003 | -1,215 | -1,749 | 726 | -1,934 | -608 | |
| Cash & Cash Eqvt | 4,359 | 7,286 | 8,032 | 8,642 | 7,906 | 7,062 | 5,677 | 6,273 | 4,508 | 4,624 |
|
Fri, 19 Apr 2024
Updates Sun Pharmaceutical Industries Limited has informed the Exchange regarding 'Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 Regulatory Order'. |
|
Wed, 17 Apr 2024
Updates Sun Pharmaceutical Industries Limited has informed the Exchange regarding 'Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 Regulatory Order'. |
|
Thu, 11 Apr 2024
Updates Sun Pharmaceutical Industries Limited has informed the Exchange regarding 'Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 Dadra facility receives OAI status from US FDA'. |
| Mon, 22 Apr 2024 |
Closing Above Previous High
|
Close Within 52 Week High Zone
|
High Increase in 3 Months
|
High Increase in 6 Months
|
High Increase in 1 Year
|
